araag2/HINT huggingface dataset:
Clinical trial NCT00441025 (phase 2, status: terminated)
Conditions: peripheral t-cell lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: alemtuzumab
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Reason stopped: 
    a lack of a potential patient.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have a diagnosis of one of the following histologic types according to
             the WHO classification:

               -  Angioimmunoblastic T-cell lymphoma

               -  Extranodal NK/T-cell lymphoma,nasal type

               -  Enteropathy-type T-cell lymphoma

               -  Hepatosplenic gamma-delta T-cell lymphoma

               -  Subcutaneous panniculitis-like T-cell lymphoma

               -  Anaplastic large-cell lymphoma,T/null cell,primary systemic type

               -  Peripheral T-cell lymphoma,not otherwise characterized

          -  Newly diagnosed,age 15-65 years.

          -  Complete work up for baseline evaluation and measurement (Appendix B)

          -  Patient's free written inform consent.

        Exclusion Criteria:

          -  Patients with a known hypersensitivity to murine proteins or to any component of
             alemtuzumab.

          -  Patients who have received prior antilymphoma treatment with chemotherapy or
             radiotherapy

          -  Patients with poor performance status (PS;ECOG criteria of 3-4)(Appendix C).

          -  Serologic evidence of HCV and HCV RNA of chronic hepatitis.

          -  Serologic evidence of HBV and HBV RNA of chronic hepatitis.

          -  Patients with history of impaired cardiac status or myocardial infarction.

          -  Patients with serum creatinine >= 1.8 mg/dl,bilirubin >= 1.5 times upper limit of
             normal range,SGOT or SGPT >= 3 times upper limit of normal range, unless due to tumor
             involvement.

          -  Patients with active uncontrolled infection,active non-malignant gastric or duodenal
             ulcer, uncontrolled diabetes mellitus or other severe medical conditions which would
             preclude aggressive cytotoxic chemotherapy.

          -  Active secondary malignancy.

          -  Pregnant or lactating women.

          -  Serious medical or psychiatric illness which prevent informed consent.

          -  Patients who are likely to lost to follow up (eg, unwilling or difficult to
             return,cannot be contacted).
Clinical trial NCT01420523 (phase 2, status: terminated)
Conditions: human immunodeficiency virus, lipohypertrophy
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: raltegravir-maraviroc
SMILES: CC(C)C1=NN=C(C)N1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients infected with HIV-1 type B or CRF02.

          -  ≥ 18 years old

          -  Patients who have been receiving antiretroviral therapy for at least 5 years, and
             whose treatment has been stable for at least 6 months.

          -  Patients whose plasma viral load has been undetectable (below 200 copies/mL) over the
             last 24 months, and < 50 copies/mL for at least 12 months.

          -  Patients with an R5* tropic virus, as determined through DNA and with CD4 nadir ≥
             100/mm3

          -  Patients presenting with clinical lipohypertrophy recognized by themselves and by
             their doctors, and defined by increased volume of the abdominal and/or thoracic and/or
             cervical area (buffalo hump).

          -  Patients who have never been treated with raltegravir.

          -  Patients who have never been treated with maraviroc.

          -  Efficient contraception for women

          -  Free and informed written consent, signed by the patient and the investigator.

          -  Patients with health insurance. * To increase the certainty of selecting patients with
             an R5 virus, the HIV-1 tropism will be determined by the genotype method and
             interpreted with the Geno2pheno[coreceptor] algorithm and a false positive rate
             threshold for X4 virus at 20%, rather than the usual 10%.

        Exclusion Criteria:

          -  X4, X4/5 or undetermined tropism of the HIV virus.

          -  HIV-2 or coinfection HIV-1/HIV-2.

          -  Chronic viral hepatitis B.

          -  Chronic viral hepatitis C requiring specific treatment over the first 24 weeks.

          -  Treatment with growth hormones.

          -  Hypolipemic or diabetes treatment, begun within the last 3 months.

          -  Pregnant or breastfeeding women.

          -  Haemoglobin < 7g/dl, neutrophils < 500/mm3, platelets < 50 000/mm3, creatinine
             clearance < 50 mL/min, alkaline phosphatases, ASAT, ALAT or bilirubin ≥ 3 times the
             upper limit of the normal range (N).

          -  Antiretroviral treatment associated to enzymatic inducer.

          -  Chronic alcohol consumption.

          -  Subjects under "sauvegarde de justice" (judicial protection due to temporarily and
             slightly diminished mental or physical faculties), or under legal guardianship.

          -  Subjects participating in another clinical trial evaluating different therapies and
             including an exclusion period that is still in force during the screening phase.
Clinical trial NCT01062490 (phase 2, status: completed)
Conditions: myelodysplastic syndrome
ICD codes: D46.9, D46.C, D46.Z
Drugs: treosulfan
SMILES: CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with myelodysplastic syndrome, (MDS) according to WHO classification (< 20 %
             myeloblasts in peripheral blood or bone marrow at initial diagnosis) indicated for
             allogeneic transplantation

          2. Availability of an HLA-identical sibling donor (MRD) or HLA-identical unrelated donor
             (MUD) HLA-identity defined by the following markers: HLA-A, -B, -DRB1, DQB1.

          3. Target graft size (unmanipulated) bone marrow: 2 to 10 x 106 CD34+ cells/kg BW
             recipient or at least 2 x 108 nucleated cells /kg BW or peripheral blood: 4 to 10 x
             106 CD34+ cells/kg BW recipient

          4. Age > 18 and < 60 years

          5. Karnofsky Index > 80 %

          6. Adequate contraception in female patients of child-bearing potential

          7. Written informed consent

        Exclusion Criteria:

          1. 'Secondary' or therapy-related MDS with known history of exposure to cytotoxic
             alkylating drugs and/or radiation therapy

          2. Previous AML-induction therapy with more than two courses (e.g. in case of blast
             excess)

          3. Previous allogeneic transplantation

          4. Severe concomitant illnesses / medical conditions (e.g. impaired respiratory and/or
             cardiac function)

          5. Known and manifested malignant involvement of the CNS

          6. Active infectious disease

          7. HIV- positivity or active hepatitis infection

          8. Impaired liver function (Bilirubin > upper normal limit; Transaminases > 3.0 x upper
             normal limit)

          9. Impaired renal function (Creatinine-clearance < 60 ml/min; Serum Creatinine > 1.5 x
             upper normal limit).

         10. Pleural effusion or ascites > 1.0 L

         11. Pregnancy or lactation

         12. Known hypersensitivity to treosulfan and/or fludarabine

         13. Participation in another experimental drug trial within 4 weeks before study

         14. Non-co-operative behaviour or non-compliance

         15. Psychiatric diseases or conditions that might impair the ability to give informed
             consent
Clinical trial NCT00214890 (phase 2, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: tenofovir, abacavir
SMILES: C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          1. HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by Western
             blot at any time prior to study entry. HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA,
             or a second antibody test by a method other than ELISA is acceptable as an alternative
             confirmatory test.

          2. Antiretroviral naïve defined as no prior therapy.

          3. CD4+ cell count > than 200 cells/ mm3 determined by site clinical laboratory within 90
             days of screening.

          4. HIV-1 RNA level > 5000 copies/mL obtained by site clinical laboratory within 90 days
             of screening.

          5. Laboratory values obtained by screening laboratories within 30 days of entry:

               -  Absolute neutrophil count (ANC) ≥ 750/mm3.

               -  Hemoglobin ≥ 8.0 g/dL.

               -  Platelet count ≥ 50,000/mm3.

               -  Calculated creatinine clearance (CrCl) > 50 mL/min as estimated by the

               -  AST (SGOT), ALT (SGPT), and alkaline phosphatase ≤ 5 x ULN.

               -  Total bilirubin ≤ 2.5 x ULN.

          6. Negative serum or urine pregnancy test within 30 days of study entry.

          7. Karnofsky performance score ≥ 70.

          8. Men and women age ≥ 18 years.

          9. Ability and willingness of subject to give written informed consent.

        Exclusion Criteria:

          1. Any NRTI or NNRTI-associated resistance mutations as defined by the updated
             International AIDS Society-USA (IAS-USA) mutation list.

          2. Pregnancy and breast-feeding.

          3. Active drug or alcohol use or dependence that, in the opinion of the investigator,
             would interfere with adherence to study requirements.

          4. Urgent need to initiate antiretroviral therapy, as determined by the patient's primary
             provider.

          5. Serious illness (requiring systemic treatment and/or hospitalization) until subject
             either completes therapy or is clinically stable on therapy, in the opinion of the
             investigator, for at least 14 days prior to study entry.

          6. Use of any immunomodulator, HIV vaccine, or investigational therapy within 30 days of
             study entry.

          7. Use of human growth hormone within 30 days prior to study entry.

          8. Initiation of testosterone or anabolic steroids within 30 days prior to study entry.
             (Exception: Chronic replacement dosages in patient's with diagnosed hypogonadism is
             allowed)
Clinical trial NCT00168454 (phase 2, status: completed)
Conditions: overactive bladder, urinary incontinence
ICD codes: N32.81, N39.492, R32, R39.81, N39.498, L24.A2
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must be between 18-85 years old

          -  Must have been diagnosed by his/her doctor with overactive bladder at least 6 months
             ago

          -  Must weigh at least 50 kg (110 lbs)

          -  Must be willing and able to record information regarding bladder function into a diary
             (provided)

          -  Must be willing and able to complete the entire course of the study

        Exclusion Criteria:

          -  Cannot currently be catheterizing as a way to control incontinence

          -  Must not have used botulinum toxin type A or any other botulinum toxin previously for
             any condition
Clinical trial NCT01042795 (phase 2, status: terminated)
Conditions: urothelial carcinoma, bladder cancer
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: sunitinib
SMILES: CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
Reason stopped: 
    study closed due to poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic diagnosis of bladder carcinoma (>50% urothelial carcinoma)

          -  Prior treatment with at least one cycle of platin-based neoadjuvant chemotherapy

          -  Prior treatment with radical cystectomy revealing pT3NxM0 or pTanyN+M0

          -  ECOG performance status of 0-1 (Appendix 2).

          -  No evidence of metastases within 4 weeks of registration

          -  Adequate organ and marrow function obtained within 14 days of registration

        Exclusion Criteria:

          -  Severe or uncontrolled acute or chronic medical or psychiatric condition

          -  Prior antiangiogenic therapy

          -  Prior pelvic radiation for bladder cancer
Clinical trial NCT01475461 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo, pf-04937319 - 3mg, pf-04937319 - 20mg, pf-04937319 - 50mg, pf-04937319 - 100mg, sitagliptin - 100mg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F
Eligibility criteria:

        Inclusion Criteria:

          -  patients with type 2 diabetes, on metformin, age between 18-55 yrs, male or female

        Exclusion Criteria:

          -  patients with type 1 diabetes, medically unstable, unacceptable clinical laboratory
             test results at screening
Clinical trial NCT01331850 (phase 2, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: copegus, copegus, pegasys, pegasys, ro5024048, danoprevir, ritonavir
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CC(C)C(=O)OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1CC2=CC=CC(F)=C2C1)C(=O)NS(=O)(=O)C1CC1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients, age 18 years and older

          -  Presence of hepatitis C infection, genotype 1a or 1b

          -  Documentation of previous treatment failure after receiving approved doses of
             peginterferon plus ribavirin for at least 12 weeks

          -  Patients must have discontinued prior hepatitis C treatment at least 12 weeks prior to
             study start

        Exclusion Criteria:

          -  Infection with any hepatitis C genotype or subtype other than genotype 1a or 1b

          -  Patients with cirrhosis

          -  Patients who were discontinued from previous peginterferon plus ribavirin therapy due
             to reasons other than insufficient therapeutic response

          -  Co-infection with hepatitis B or human immunodeficiency virus (HIV)

          -  History or evidence of chronic liver disease other than hepatitis C
Clinical trial NCT01499563 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: iti-007, placebo, risperidone
SMILES: [H][C@]12CCN(CCCC(=O)C3=CC=C(F)C=C3)C[C@@]1([H])C1=CC=CC3=C1N2CCN3C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Patient's age is 18-55

          -  Patient has current diagnosis of schizophrenia and is experiencing an acute
             exacerbation of psychosis

          -  Patient has a history of at least three months exposure to one or more antipsychotic
             therapy(ies) and a prior response to antipsychotic therapy within the previous five
             years

        Exclusion Criteria:

          -  Any female patient who is pregnant or breast-feeding

          -  Any patient presenting with concurrent dementia, delirium, mental retardation,
             epilepsy, drug-induced psychosis, or history of significant brain trauma

          -  Any patient presenting with schizoaffective disorder, bipolar disorder, acute mania,
             or major depression with psychotic features

          -  Any patient considered to be an imminent danger to themselves or others

          -  Any patient with hematological, renal, hepatic, endocrinological, neurological, or
             cardiovascular disease or substance abuse as defined by protocol

          -  Any patient judged by the Investigator to be inappropriate for the study
Clinical trial NCT01156753 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: cdx-011, "investigator's choice" chemotherapy
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

        Among other criteria, patients must meet all of the following conditions to be eligible for
        the study:

          1. 18 years of age or older.

          2. Locally advanced or metastatic breast cancer.

          3. Previous treatment with at least two but no more than seven prior chemotherapy
             treatments for progressive, recurrent or metastatic breast cancer.

          4. Unless not a candidate for these agents, prior therapies must have included a taxane,
             an anthracycline, and capecitabine, as well as trastuzumab and lapatinib for patients
             whose tumors are positive for the human epidermal growth factor receptor 2 (HER2).
             (Patients who received incomplete courses of therapy with these agents due to
             intolerance will be eligible.)

          5. Breast cancer tumor confirmed to express GPNMB. This will be determined by submitting
             a tissue sample (obtained during a diagnostic biopsy or surgery) to a central
             laboratory for analysis.

        Exclusion Criteria:

        Among other criteria, patients who meet any of the following conditions are NOT eligible
        for the study:

          1. Ongoing neuropathy or other chemotherapy or radiation-related toxicities that are
             moderate (Grade 2) or worse in severity.

          2. Known brain metastases, unless previously treated and asymptomatic for 2 months and
             not progressive in size or number for 2 months.

          3. Significant cardiovascular disease or any other underlying medical condition that, in
             the Investigator's opinion, will make the administration of study treatment (CDX-011
             or chemotherapy) hazardous or would obscure the interpretation of side effects.
Clinical trial NCT01018550 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: amg 853, amg 853, amg 853, amg 853, placebo
SMILES: CC(C)(C)NC(=O)C1=CC=C(OC2=CC(F)=C(CC(O)=O)C=C2Cl)C(NS(=O)(=O)C2=CC=C(C=C2Cl)C2CC2)=C1, CC(C)(C)NC(=O)C1=CC=C(OC2=CC(F)=C(CC(O)=O)C=C2Cl)C(NS(=O)(=O)C2=CC=C(C=C2Cl)C2CC2)=C1, CC(C)(C)NC(=O)C1=CC=C(OC2=CC(F)=C(CC(O)=O)C=C2Cl)C(NS(=O)(=O)C2=CC=C(C=C2Cl)C2CC2)=C1, CC(C)(C)NC(=O)C1=CC=C(OC2=CC(F)=C(CC(O)=O)C=C2Cl)C(NS(=O)(=O)C2=CC=C(C=C2Cl)C2CC2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females 18 to 65 years of age

          -  Percent of predicted FEV1 ≥ 50% and ≤ 80%

          -  At least 12% reversibility over pre-bronchodilator FEV1

          -  Inhaled corticosteroid (ICS) ≥ 200 and ≤ 1000 µg/day fluticasone or equivalent.

          -  Ongoing asthma symptoms with ACQ score ≥ 1.5 points

        Exclusion Criteria:

          -  History of chronic obstructive pulmonary disease or other chronic pulmonary condition
             other than asthma

          -  Any uncontrolled, clinically significant systemic disease

          -  Respiratory infection within 4 weeks of the screening visit
Clinical trial NCT00403754 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: indacaterol, placebo, salmeterol
SMILES: CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female Japanese asthmatic patients aged 18 to 75 years old.

        Exclusion Criteria:

          -  Patients who have been hospitalized or had emergency room treatment for an acute
             asthma attack in the 6 months prior to the first day of screening or during the
             screening period.

          -  Patients who have used tobacco products within 6 months prior to the first day of
             screening or have a smoking history of greater than 10 pack years.

          -  Patients with a history of malignancy with the exception of localized basal cell
             carcinoma of the skin.

          -  Pregnant or nursing (lactating) women.

          -  Patients who have had treatment with disallowed medications including investigational
             drug.

        Other protocol-defined inclusion/exclusion criteria applied to the study.
Clinical trial NCT00656006 (phase 2, status: completed)
Conditions: chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: albuferon, ribavirin
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Have a clinical diagnosis of chronic hepatitis C on the basis of detectable serum HCV
             RNA during the screening period and at least a 6-month history of exposure to risk
             factors for HCV.

          -  Have never received treatment with an interferon alfa product or an interferon alfa
             combination product.

          -  Have HCV genotype 2 or 3.

          -  Have compensated liver disease with the following minimum criteria: white blood cell
             count (WBC) >3,000/mm3, absolute neutrophil count (ANC) > 1,800/mm3, platelets
             >100,000/mm3, hemoglobin (Hb) > 13 g/dL for males and > 12 g/dL for females.

        Exclusion Criteria:

          -  Evidence of decompensated liver disease.

          -  Pregnant or lactating female.

          -  History of any other medical disease or condition that would make the subject (in the
             opinion of the investigator) unsuitable for the study.

          -  A current drug or alcohol addiction.
Clinical trial NCT00298688 (phase 2, status: completed)
Conditions: small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: gefitinib
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of written informed consent

          -  Histologically confirmed, relapsed or refractory SCLCr

          -  Aged 18 or over and a life expectancy of more than 2 months

        Exclusion Criteria:

          -  Any evidence of clinically active interstitial lung disease

          -  Other co-existing malignancies or malignancies diagnosed within the last 5 years, with
             the exception of basal cell carcinoma or cervical cancer in situ.
Clinical trial NCT00118755 (phase 2, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: capecitabine, oxaliplatin, bevacizumab, capecitabine, oxaliplatin, bevacizumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Metastatic or inoperable locally advanced colorectal cancer

          -  >=1 measurable target lesion

        Exclusion Criteria:

          -  Previous systemic therapy for advanced or metastatic disease

          -  Previous treatment with bevacizumab